Trials / Completed
CompletedNCT04748185
Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With Hematologic Malignancies
Immunogenicity and Safety of Commercially Available Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients With Hematologic Malignancies and Associated Precursor Conditions
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 358 (actual)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
D1. Primary Objective: 1\. Determine the immunogenicity of FDA approved COVID-19 vaccination in patients with hematologic malignancies D2. Secondary Objectives: 1. Assess the safety of FDA approved COVID-19 vaccination in patients with hematologic malignancies 2. Analyze the kinetics of immunogenic response over time after receipt of the COVID-19 vaccination 3. Compare the immunogenicity of different COVID-19 vaccinations that will be approved by the FDA 4. Analyze advanced flow immunophenotyping of innate and adaptive immune blood cells in all participants and correlate with response to vaccination
Conditions
- Monoclonal B-Cell Lymphocytosis
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- B-cell Non Hodgkin Lymphoma
- Hodgkin Lymphoma
Timeline
- Start date
- 2021-01-28
- Primary completion
- 2022-07-13
- Completion
- 2022-07-13
- First posted
- 2021-02-10
- Last updated
- 2023-07-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04748185. Inclusion in this directory is not an endorsement.